Maxx Chatsko

Maxx Chatsko

TMFBlacknGold

Maxx has been a contributor to Fool.com since 2013. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering.

Recent articles





Is Dow Inc. a Buy?

The new materials science company is eager to deliver consistent performance -- and a 6% annual dividend yield -- courtesy of its far-reaching product portfolio.

Is Rigel Pharmaceuticals a Buy?

The stock rose after a promising full-year 2018 earnings report and then rapidly began sliding back to multiyear lows. What's going on?




Is DuPont a Buy?

The new specialty materials company will have the highest operating margin of the three DowDuPont spinoffs.



Here's Why 3M Fell 15.7% in May

Investors continued to sell the news of a weak Q1 earnings report, but management made things worse with a controversial acquisition.


Is Codexis a Buy?

The biotech expects double-digit revenue growth in 2019, but shares have fallen 21% since the end of March.



Is Axovant Gene Therapies a Buy?

The small-cap biopharma started 2019 with a rising stock price and a new focus on gene therapies, but it's been a rocky transition.